Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.
Fiche publication
Date publication
avril 2018
Journal
JAMA oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis, Pr DECONINCK Eric
Tous les auteurs :
Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL,
Lien Pubmed
Résumé
Pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity.
Référence
JAMA Oncol. 2018 Apr 1;4(4):468-475